Explore the groundbreaking realm of preventive cardiology as we delve into the potential of an atherosclerosis vaccine and its implications for the future of heart health.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?
Surma et al., Curr Atheroscler Rep 2024
DOI: 10.1007/s11883-023-01186-z
Development of Anti-PCSK9 Vaccine for Lipid Disorders
New Information: Research into an anti-PCSK9 vaccine as a novel approach for long-term control of low-density lipoprotein cholesterol (LDL-C) levels.
Importance: Atherosclerotic cardiovascular disease (ASCVD) is a major cause of premature death, with lipid disorders playing a key role. The concept of “cholesterol-years” suggests that prolonged exposure to high LDL-C increases ASCVD risk. Current lipid-lowering treatments are not always effective due to challenges in achieving control and maintaining patient adherence.
Contribution to Literature: The anti-PCSK9 vaccine represents a potential breakthrough in lipid management by offering an annual administration option. This could improve treatment adherence and provide sustained lipid-lowering effects. Initial experimental studies and a clinical trial have shown promising results in terms of inducing a durable immune response, lowering lipid levels, and providing anti-atherosclerotic benefits. The vaccine has also shown good tolerability and safety. However, further data from phase 2, 3, and cardiovascular outcome trials are needed to confirm its safety and efficacy.
Summary: The article underscores the potential of an anti-PCSK9 vaccine to revolutionize the treatment of lipid disorders and extend lifespan by reducing cardiovascular risk. It also reviews the current status of various anti-PCSK9 vaccines under investigation.